PT-141 10MG

PT-141 (Bremelanotide) is a synthetic peptide that acts on melanocortin receptors and has been studied for its role in sexual desire and related signaling pathways. Bremelanotide is the active ingredient in the FDA-approved medicine Vyleesi, which is indicated specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

PT-141 10mg is commonly supplied as a research peptide for laboratory investigation of melanocortin receptor activity, neurological signaling, and sexual-function-related pathways.

Research Areas:

Melanocortin receptor signaling
Sexual desire and behavioral research
Neuroendocrine signaling
CNS peptide research
Receptor pharmacology
Peptide mechanism studies

Research Use Only — Not for human or veterinary use.

Note: The FDA-approved bremelanotide product is supplied at 1.75 mg per dose; a 10 mg research-vial strength is not equivalent to the approved product or its labeled dosing.